Warren Eric sold $2.7M of MLYS
Warren Eric (Chief Commercial Officer) sold 104,124 shares of Mineralys Therapeutics, Inc. (MLYS) at $25.90 ($2.70M total) on 2026-06-26 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The disclosure provides a concrete datapoint on insider selling volume and pricing, but the 10b5-1 structure generally limits interpretive impact.
Market read
A reported insider sale at a specific price and date, but with 10b5-1 pre-arrangement, implying low incremental fundamental information.
What to watch
The filing doesn’t disclose intent beyond the plan; traders should avoid over-weighting single insider sales without follow-on buys/sales patterns or fundamental catalysts.
Background
SEC Form 4 insider transaction for Mineralys Therapeutics, Inc. (MLYS) filed 2026-06-30.
Ticker impact
Form 4 shows Mineralys Therapeutics CCO Warren Eric sold 104,124 shares at $25.8953 on 2026-06-26 under a 10b5-1 plan.
Likely minimal immediate price impact; any effect is more sentiment-driven than fundamental.
The filing is a primary insider transaction disclosure, but it explicitly cites a pre-arranged 10b5-1 plan, which reduces interpretive weight versus discretionary selling.
Market effects
No sector read-across; this is company-specific insider activity.
None indicated.
None indicated.
Counterpoint
The sale may be purely liquidity/tax-driven under the 10b5-1 plan, offering little to no bearish information.
Key entities
- issuerMineralys Therapeutics, Inc.
Subject of the Form 4 insider transaction disclosure.
- insiderWarren Eric
Chief Commercial Officer who sold shares.
- trading mechanism10b5-1 plan
Pre-arranged plan cited for the sale, reducing discretionary-signal strength.
